Table 2 Demographic and baseline characteristics of the pooled safety population
Eptinezumab | Placebo | ||||||
|---|---|---|---|---|---|---|---|
1000 mg | 300 mg | 100 mg | 30 mg | 10 mg | All | ||
N | 81 | 823 | 701 | 341 | 130 | 2076 | 791 |
Population | EM | EM + CM | EM + CM | EM + CM | CM | EM + CM | EM + CM |
Mean (SD) age, years | 38.6 (10.8) | 40.3 (10.9) | 39.9 (11.1) | 37.9 (10.9) | 36.4 (10.3) | 39.5 (11.0) | 39.3 (11.0) |
Mean (SD) BMI, kg/m2 | 27.5 (5.2) | 27.4 (5.8) | 27.6 (6.1) | 28.9 (7.6) | 27.4 (5.4) | 27.7 (6.2) | 27.9 (6.1) |
Sex, % female | 82.7 | 87.5 | 84.2 | 86.8 | 86.9 | 86.0 | 86.7 |
Race, %a | |||||||
White | 81.5 | 90.5 | 90.7 | 83.0 | 86.9 | 88.8 | 85.6 |
Black/African American | 12.3 | 7.0 | 7.1 | 13.2 | 9.2 | 8.4 | 10.6 |
Asian | 4.9 | 0.5 | 0.3 | 0.3 | 0.8 | 0.6 | 0.9 |
American Indian/Alaska Native | 0 | 0.4 | 0.1 | 0.3 | 1.5 | 0.3 | 0.4 |
Native Hawaiian/Pacific Islander | 0 | 0.2 | 0.1 | 0.3 | 0 | 0.2 | 0.3 |
Multiple races | 1.2 | 1.1 | 1.3 | 1.5 | 0 | 1.2 | 1.6 |
Other | 0 | 0.1 | 0.3 | 1.5 | 1.5 | 0.5 | 0.6 |
Not reported | 0 | 0.1 | 0 | 0 | 0 | < 1 | 0 |